“The first questions many patients ask aren't about the virus itself,” says Junhyun Han, director of Power Urology Clinic in South Korea. “Instead, they ask, 'Will I ever be able to get married?' 'Do I have to tell my partner?' or 'Will people think I'm promiscuous?'” he said. For many patients, he added, “the fear of social judgment and how the diagnosis might affect their relationships is much greater than concern about the infection itself. Medically, however, HSV is an extremely common virus, and an HSV diagnosis tells us nothing about a person's lifestyle or moral character.”
Herpes Simplex Virus (HSV) infects most of the adult world by the time it's middle-aged. Global estimates put HSV-1 prevalence at 66.6 percent of people under 50 and HSV-2 at 13.2 percent. In South Korea specifically, reported HSV-2 cases have more than tripled in less than a decade, from roughly 3,550 in 2014 to 11,450 in 2023.
The vaccine has been being worked on for the last seventy years. But the way HSV works has prevented many breakthroughs. Most vaccines work by training the immune system to eliminate a pathogen (a biological agent or microorganism that causes disease in its host) before it establishes a foothold. HSV makes that nearly impossible because of where it retreats.
Han explains that the biggest reason for a lack of vaccine is that HSV is a “virus that hides inside our body's nerve cells.” Most vaccines aim to use an immune response to block the virus before it enters the body. Han suggests, however, that “HSV infects the skin or mucous membranes and then very quickly travels along sensory nerves to become latent inside a ganglion (a nerve cell cluster).”
“Once it enters this latent state, the virus is barely active, so immune cells have a hard time detecting it as well,” he added. “On top of all that complications, HSV also has several proteins that help it evade the immune response, which is why it's considered one of the most difficult viruses to develop a vaccine against,” Han said.
In short: the virus doesn't stay where the immune system can watch it. It ducks into neurons, cells the immune system barely surveils, and goes quiet there for life, waking up periodically to cause new outbreaks or silent shedding. A vaccine can only train an immune response to fight what it can see, and HSV's hiding spot is largely invisible to it.
If a vaccine is closer, it isn't obvious from the headlines of the past two years, which have mostly been about programs closing rather than opening.
In September 2024, GSK halted its HSV vaccine candidate, GSK3943104, after a Phase I/II trial failed to meet its primary efficacy goal, even though no safety concerns emerged. In November 2025, Moderna followed suit, announcing it would not advance its mRNA-based candidate, mRNA-1608, into Phase 3 testing, and the company's 2025 annual report lists the HSV program among several it has discontinued as part of a broader pipeline prioritization. Both candidates had generated meaningful immune responses in earlier trials, but neither translated that into a real-world drop in outbreaks or transmission, underscoring a point researchers keep running into: getting the immune system to react isn't the same as getting it to protect.
One prophylactic candidate is still moving. BioNTech's BNT163, developed with the University of Pennsylvania and designed to prevent genital lesions from HSV-2 (and potentially HSV-1), remains in a Phase 1 trial studying safety, tolerability, and immune response in both HSV-negative and HSV-positive volunteers. The study's completion date has been pushed from April to October 2026, and no efficacy data has been reported yet, so it remains investigational rather than a near-term product.
There's also movement outside the vaccine lane entirely. Assembly Biosciences reported that its long-acting antiviral candidate, ABI-5366, cut viral shedding by 94 percent compared to placebo in a Phase Ib trial of people with recurrent genital HSV-2—well above the company's own 80–85 percent target—and the drug is advancing to Phase II trials in mid-2026 in partnership with Gilead. It isn't a vaccine and wouldn't prevent infection, but a therapy that can suppress shedding that effectively would meaningfully reduce both outbreaks and transmission risk for people who already have HSV.
Taken together, the state of the science in 2026 is that no HSV vaccine is approved or imminent, the two most closely watched prophylactic vaccine candidates of the past few years have both stumbled, and the most promising near-term relief may come from better antivirals rather than a vaccine at all.
But what makes the virus truly feel incurable, according to patients and experts, is how the world looks at—and treats—the virus.
Because herpes is sexually transmitted, HSV has been historically viewed as a "lifestyle consequence" rather than a serious public health priority. Prominent immunologists, such as Dr. Akiko Iwasaki at Yale University (who developed a highly successful therapeutic vaccine for guinea pigs), have spoken to the press about how difficult it is to secure pharmaceutical investment. Despite patients pleading for a cure, companies have historically shied away from prioritizing HSV over other viral illnesses simply because it is a taboo subject that people are afraid to talk about openly. This isn't just a perception among patients. Advocacy groups point to the data: despite affecting more people worldwide than diabetes, cancer, and heart disease combined, herpes research remains critically underfunded, and since the first herpes treatment was approved back in 1982, there has been no significant medical innovation in treatment or diagnostics for the virus.
And the greatest irony of HSV is that biologically, it is a relatively minor, highly manageable skin condition for the vast majority of people. The most severe symptom of the virus is almost always the societal shame attached to it. A 2011 study of women living with genital herpes found that perceived stigma and coping strategies together explained nearly two-thirds of the variance in participants' quality of life.
Separate research on chronic genital herpes patients found that stigma was directly tied to whether people disclosed their status to sexual partners at all, with roughly a third of patients in one UK sample reporting moderate to severe anxiety tied to their diagnosis. A more recent survey of U.S. undergraduates found that more than half said they felt they could not cope with a genital herpes outbreak, even though most respondents said they'd still be open to dating someone with a history of the virus, suggesting the stigma may be felt more sharply by patients themselves than it is actually held by their peers.
Some legal cases reinforce the stigma, too. Take, for instance, the 2026 Australian Criminal Conviction. In May 2026, a landmark case in Australia made international headlines when a man was convicted of "recklessly inflicting grievous bodily harm" and sentenced to 13 months for transmitting HSV-2 to a partner. He was asymptomatic at the time, but had not disclosed his status. Public health experts and researchers argued heavily against this ruling, warning that treating a common virus like a violent crime drastically escalates stigma and discourages people from getting tested.
Recent news in the US also frequently features multi-million dollar civil lawsuits over herpes transmission. For example, a recent seven-figure settlement in New York and highly publicized lawsuits involving dating apps in Los Angeles frame HSV-2 as a "life-altering" and devastating injury. When the legal system and media treat a virus as a catastrophic fraud or assault, it terrifies the public and deeply shames those living with it.
The online culture makes it even worse. A 2019 investigation found that more than 1,000 Reddit posts contained the words "herpes" and "devastated," and search engines still reflect the same anxiety: autocomplete suggestions for herpes-related queries are dominated by phrases like "how to date with herpes" and "is my life over with herpes," reinforcing the idea that a diagnosis is catastrophic before a patient has even had the chance to learn the medical facts.
Media has also added significantly to the felt stigma. In a movie Contagion released in 2011, the husband of Beth Emhoff, the very first patient of an unknown virus in the movie, is seen to lash out at a doctor’s suggestion that she might have had herpes while explaining the cause of her death. Gossip Girl, a popular TV show aired from 2007 to 2012, one of the characters Vanessa Abrams is seen to donate money to a foundation for teens with genital herpes as a means to humiliate Chuck Bass, another character she’s posed against.
Despite all the videos on the internet by the physicians trying to educate and therefore de-stigmatize the virus, the comments look discouraging: “I’d rather not have herpes,” one user of YouTube commented, while another simply asked, "Why did this pop up on my YouTube?"—a reaction that reveals just how uncomfortable people still are with the topic being surfaced at all, let alone discussed openly.
But experts say that such social stigma around HSV is way out of proportion to the medical reality of it.
“Herpes is, medically speaking, a very common virus,” Han said. “But it has so often been portrayed in sensationalized ways by the media and popular culture,” he added. “Also, the word ‘herpes’ itself has become so strongly nuanced with someone’s sexual choices or lifestyle choices, leading many people to make unfair assumptions about an individual's sexual behavior simply because they have been diagnosed. From a medical standpoint, HSV is an extremely common virus, and infection alone should never be viewed as a reflection of a person's morality or sexual behavior,” Han said.
Yong Jae Yang, a Professor Emeritus at St. Mary's Women's Hospital, said: “The number of HSV patients isn't small. I see around 30 or so outpatients a day, and at least once every 2-3 days, I encounter one or more genital herpes patients. I explain that since there can be a gap between the time of viral infection and the time symptoms appear, it can't necessarily be assumed to be a recent infection.”
There are positive signs to that side of curing all that the virus carries. A YouTube video by a Black female doctor has gone viral, and grassroots efforts have followed a similar path. Courtney Brame, who was diagnosed with HSV-2, started the podcast "Something Positive for Positive People" in 2017 after noticing how much people in private support groups struggled with the stigma of their diagnosis, in some cases to the point of suicidal thoughts, and the podcast has since grown into a community of more than 27,000 listeners. Similar creator-led efforts have spread across TikTok and Instagram, where people living with HSV post educational content and personal disclosure stories aimed at normalizing the virus rather than hiding it.
There was also a time that an entire country turned compassionate towards herpes. In October 2024, the New Zealand Herpes Foundation and agency Motion Sickness launched the campaign locally. The video course, country leaderboard, and national media push ran heavily through late 2024 and early 2025, racking up millions of views and over 10,000 hours of watched educational content within its first two months.The campaign received international acclaim and swept six awards, including two Grand Prix, at the 72nd Cannes Lions International Festival of Creativity in June 2025.
The campaign was born out of an "impossible brief" that the New Zealand Herpes Foundation had been mulling over for nearly a decade: How do you de-stigmatize a virus that has been the punchline of jokes for decades? At the time, New Zealanders were feeling a bit down. The country had recently lost the Rugby World Cup, faced economic pressures, and experienced major political shifts. The agency decided to joke that while New Zealand might not be #1 in rugby right now, it could become the #1 most educated, compassionate, and stigma-free nation in the world for herpes.
Such work, experts argue, must continue. “Going forward, rather than stigmatizing those who are infected, we should place greater emphasis on providing accurate information, promoting preventive education, and supporting continued research toward an effective vaccine,” Han said.
That's the world the next generation inherits: a virus a number of them will carry in some form, and a silence that's outlasted every attempt to cure it. Science may eventually catch up. But stigma doesn't wait for a lab result to loosen its grip.